Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance

Blood Purification

Volumn 26, Issue 2, 2008, Pages 213-220

  Chu, Pei Lun ^a,b   Chiu, Yen Ling ^c   Lin, Jou Wei ^b   Chen, Shih I ^b   Wu, Kwan Dun ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

8 Iso prostaglandin F2 ; Adiponectin; Endothelial dysfunction; Hemodialysis; Insulin resistance; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; INSULIN;

ANTIOXIDANT ACTIVITY; ARTICLE; ARTIFICIAL KIDNEY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADIPONECTIN; AGED; CARDIOVASCULAR DISEASES; DINOPROST; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 40949142394     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000117440     Document Type: Article

References (36)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119.
2. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-152.
3. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J: Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:2570-2575.
4. Migliacci R, Falcinelli F, Imperiali P, Floridi A, Nenci GG, Gresele P: Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis. Ital Heart J 2004;5:371-377.
5. Diaz-Buxo JA, Woods HF: Protecting the endothelium: a new focus for management of chronic kidney disease. Hemodial Int 2006; 10:42-48.
6. Kosch M, Levers A, Fobker M, Barenbrock M, Schaefer RM, Rahn KH, Hausberg M: Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress. Nephrol Dial Transplant 2003;18:1370-1375.
7. Hoffmann U, Fischereder M, Marx M, Schweda F, Lang B, Straub RH, Kramer BK: Induction of cytokines and adhesion molecules in stable hemodialysis patients: Is there an effect of membrane material? Am J Nephrol 2003;23:442-447.
8. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P: Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47.
9. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, Memmos D: Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002;17: 435-441.
10. Dinarello CA: Cytokines: agents provocateurs in hemodialysis? Kidney Int 1992;41: 683-694.
11. Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, Dwyer JT, Kimmel PL, Kusek JW, Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB: Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 2004;66:355-366.
12. Ronco C, Ghezzi PM, Hoenich NA, Delfino P: Computerized selection of membranes and hemodialysers. Contrib Nephrol. Basel, Karger, 2001, vol 133, pp 119-130.
13. Clark WR, Hamburger RJ, Lysaght MJ: Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int 1999;56:2005-2015.
14. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW: Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993;3:1409-1415.
15. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA: High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995;5:1703-1708.
16. Woods HF, Nandakumar M: Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 2000;15(suppl 1):36-42.
17. Grooteman MP, Nube MJ: Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: Does it really matter? Nephrol Dial Transplant 2004;19:2965-2970.
18. Desideri G, De Simone M, Iughetti L, Rosato T, Iezzi ML, Marinucci MC, Cofini V, Croce G, Passacquale G, Necozione S, Ferri C: Early activation of vascular endothelial cells and platelets in obese children. J Clin Endocrinol Metab 2005;90:3145-3152.
19. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107:671-674.
20. Zoccali C, Mallamaci F, Tripepi G: Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19 (suppl 5):V67-V72.
21. Kim KM, Jung BH, Paeng KJ, Kim SW, Chung BC: Alteration of plasma total F2-isoprostanes before and after hemodialysis in end-stage renal disease patients. Prostaglandins Leukot Essent Fatty Acids 2004;70:475-478.
22. Shen Y, Peake PW, Kelly JJ: Should we quantify insulin resistance in patients with renal disease? Nephrology (Carlton) 2005;10:599-605.
23. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK: Effects of hemodialyzer reuse on clearances of urea and beta-2-microglobulin. The Hemodialysis (HEMO) Study Group. J Am Soc Nephrol 1999;10:117-127.
24. Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, van der Tweel I, Ter Wee PM: Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]. Curr Control Trials Cardiovasc Med 2005; 6:8.
25. Ronco C, Bowry SK, Brendolan A, Crepaldi C, Soffiati G, Fortunato A, Bordoni V, Granziero A, Torsello G, La Greca G: Hemodialyzer: from macro-design to membrane nanostructure; the case of the FX class of hemodialyzers. Kidney Int Suppl 2002;126-142.
26. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565.
27. Cross JM, Donald A, Vallance PJ, Deanfield JE, Woolfson RG, MacAllister RJ: Dialysis improves endothelial function in humans. Nephrol Dial Transplant 2001;16:1823-1829.
28. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T: Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000;101:1002-1006.
29. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, Matsuzawa Y, Cierpka L, Kokot F, Wiecek A: Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003;35:2186-2189.
30. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits-Filho R, Lonnqvist F, Schalling M, Heimburger O, Nordfors L: Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004;66:46-50.
31. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13:134-141.
32. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD: Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004;43: 1047-1055.
33. Kerr PG, Sutherland WH, de Jong S, Vaithalingham I, Williams SM, Walker RJ: The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: a randomized, single-blinded, controlled clinical trial. Am J Kidney Dis 2007;49:533-539.
34. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS: Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380-2389.
35. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO Study. J Am Soc Nephrol 2003;14:3251-3263.
36. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801.